NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its board has authorized a share buyback plan on Wednesday, February 12th 2020, which allows the company to repurchase 5,000,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Friday, January, 31st. The company reported $1.04 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.91 by $0.13. The company had revenue of $605.50 million for the quarter, compared to analyst estimates of $600.60 million. IDEXX Laboratories had a net margin of 17.77% and a return on equity of 283.27%. The firm's quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the business earned $0.98 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Friday, January, 31st. The company provided EPS guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

6 Wall Street analysts have issued 1-year target prices for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' stock price to reach $293.33 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

News articles about IDXX stock have been trending very negative on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. IDEXX Laboratories earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decrease of 6.9% from the January 15th total of 1,300,000 shares. Based on an average daily trading volume, of 507,000 shares, the short-interest ratio is presently 2.4 days. Currently, 1.4% of the shares of the stock are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Steris (STE), Varian Medical Systems (VAR), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.40%), Bamco Inc. NY (4.39%), Geode Capital Management LLC (1.82%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%) and Capital World Investors (1.28%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Bamco Inc. NY, Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was acquired by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Geode Capital Management LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $256.71.

IDEXX Laboratories has a market capitalization of $21.91 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]